Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by which it influences tumorigenesis. We show that rs6877329 G > C resides in a predicted enhancer element that physically interacts with the transcription start site of ELL2. The rs6877329-C risk allele is associated with reduced enhancer activity and lowered ELL2 expression. Since ELL2 is critical to the B cell differentiation process, reduced ELL2 expression is consistent with inherited genetic variation contributing to arrest of plasma cell development, facilitating MM clonal expansion. These data provide evidence for a biological mechanism underlying a hereditary risk of MM at 5q15.


  • Ni L. Li
  • David C. Johnson
  • Niels Weinhold
  • Scott Kimber
  • Sara E. Dobbins
  • Jonathan S Mitchell
  • Ben Kinnersley
  • Amit Sud
  • Philip J. Law
  • Giulia Orlando
  • Matthew Scales
  • Christopher P. Wardell
  • Phuc H. Hoang
  • Molly Went
  • Amy Holroyd
  • Fadi Hariri
  • Tomi Pastinen
  • Tobias Meissner
  • Hartmut Goldschmidt
  • Gareth J Morgan
  • Martin Kaiser
  • Richard S. Houlston
Enheter & grupper
Externa organisationer
  • Institute of Cancer Research London
  • University of Arkansas for Medical Sciences
  • Heidelberg University
  • German Cancer Research Centre
  • McGill University
  • Avera Cancer Institute
  • National Centre of Tumor Diseases

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Medicinsk genetik


Sidor (från-till)2556-2564
Antal sidor9
TidskriftCell Reports
StatusPublished - 2017 sep 12
Peer review utfördJa